Pharmaceuticals, Biotechnology and Life Sciences
Astellas Pharma will have an expedited review process for gilteritinib, as the U.S. Food and Drug Administration (FDA) granted fast track…
Pfizer and Astellas Pharma have announced the Phase 4 PLATO study, evaluating the efficacy and safety of continued treatment with…
Astellas Pharma and Pfizer have announced the FDA approved a supplemental New …
LEO Pharma and Japanese pharmaceutical company Astellas Pharma Inc. have entered into an Asset Purchase Agreement under which Astellas will transfer its global dermatology business to LEO Pharma for € 675 million.